Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias (AVATAR)

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by Ospedale San Donato
Information provided by (Responsible Party):
Leonardo Bolognese, MD, Ospedale San Donato Identifier:
First received: January 25, 2013
Last updated: January 30, 2013
Last verified: January 2013

A randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias

Condition Intervention Phase
Ventricular Tachycardia
Ventricular Premature Complexes
Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
Procedure: Catheter Ablation
Phase 4

Study Type: Interventional

Resource links provided by NLM:

Further study details as provided by Ospedale San Donato:

Primary Outcome Measures:
  • SF-36 score [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Quality of life improvement according to SF-36 score variations

Study Start Date: January 2013
Estimated Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Antiarrhythmic drugs
Flecainide or Propafenone or Sotalol (oral, standard dosage)
Drug: antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)
Experimental: ABLATION
Catheter Ablation
Procedure: Catheter Ablation


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following:

  1. >2000 isolated VEB/24h
  2. symptomatic monomorphic ventricular tachycardia
  3. left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy

Exclusion Criteria:

  1. known structural heart disease
  2. pregnancy
  3. life expectancy < 1 year
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01780311

Cardiovascular Department, Ospedale S.Donato Recruiting
Arezzo, AR, Italy, 52100
Contact: Pasquale Notarstefano, MD   
Principal Investigator: Leonardo Bolognese, MD, FESC         
Principal Investigator: Pasquale Notarstefano, MD         
Sub-Investigator: Simone Grotti         
Sponsors and Collaborators
Ospedale San Donato
  More Information

No publications provided

Responsible Party: Leonardo Bolognese, MD, Director, Ospedale San Donato Identifier: NCT01780311     History of Changes
Other Study ID Numbers: Arezzo008
Study First Received: January 25, 2013
Last Updated: January 30, 2013
Health Authority: Italy: Ethics Committee

Additional relevant MeSH terms:
Tachycardia, Ventricular
Ventricular Premature Complexes
Arrhythmias, Cardiac
Cardiac Complexes, Premature
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Anti-Arrhythmia Agents
Cardiovascular Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers processed this record on November 25, 2014